BamSEC and AlphaSense Join Forces
Learn More

PharmaCyte Biotech Inc.

NASDAQ: PMCB    
Share price (12/20/24): $1.64    
Market cap (12/20/24): $11.4 million

Material Contracts Filter

EX-10.5
from 8-K 20 pages Registration Rights Agreement
12/34/56
EX-10.4
from 8-K 23 pages Form of Warrant Mymd Pharmaceuticals, Inc. Warrant to Purchase Common Stock
12/34/56
EX-10.3
from 8-K 22 pages Form of Warrant Mymd Pharmaceuticals, Inc. Warrant to Purchase Common Stock
12/34/56
EX-10.2
from 8-K 37 pages Certificate of Designations of Series G Convertible Preferred Stock of Mymd Pharmaceuticals, Inc
12/34/56
EX-10.1
from 8-K 38 pages Securities Purchase Agreement
12/34/56
EX-10.4
from 8-K 12 pages Collaboration Agreement
12/34/56
EX-10.3
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 31 pages Form of Senior Unsecured Convertible Note
12/34/56
EX-10.1
from 8-K 36 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 8-K 12 pages A. Appointment of Katalyst
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 40 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 3 pages Release Agreement
12/34/56
EX-10.1
from 8-K 10 pages Separation, Consulting and Release Agreement
12/34/56
EX-10.2
from 8-K 4 pages Via Email Only August 12, 2022 Re: Director Offer Letter Dear , This Director Offer Letter Constitutes an Agreement (“Agreement”) Between You and PharmaCyte Biotech, Inc. (“Company”) and Contains All of the Terms and Conditions Relating to Your Service to the Company as a Member of Our Board of Directors (“Board”)
12/34/56
EX-10.2
from DEFA14A 4 pages Via Email Only August 12, 2022 Re: Director Offer Letter Dear , This Director Offer Letter Constitutes an Agreement (“Agreement”) Between You and PharmaCyte Biotech, Inc. (“Company”) and Contains All of the Terms and Conditions Relating to Your Service to the Company as a Member of Our Board of Directors (“Board”)
12/34/56
EX-10.1
from DEFA14A 12 pages Cooperation Agreement
12/34/56
EX-10.1
from 8-K 12 pages Cooperation Agreement
12/34/56
EX-10.42
from 10-K 11 pages 2021 Plan PharmaCyte Biotech, Inc. 2021 Equity Incentive Plan
12/34/56
EX-10.41
from 10-K 4 pages Amended and Restated Executive Compensation Agreement
12/34/56